Jupiter Topco LLC Purchases Shares of 5,236,102 Amylyx Pharmaceuticals, Inc. $AMLX

Jupiter Topco LLC bought a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) in the 2nd quarter, Holdings Channel reports. The fund bought 5,236,102 shares of the company’s stock, valued at approximately $94,014,000.

Other institutional investors have also bought and sold shares of the company. Elmind Capital LP bought a new stake in Amylyx Pharmaceuticals during the 2nd quarter valued at approximately $2,011,520,000. Hsbc Holdings PLC bought a new stake in Amylyx Pharmaceuticals in the second quarter worth $269,000. Canada Pension Plan Investment Board purchased a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at about $496,000. Parkman Healthcare Partners LLC purchased a new stake in Amylyx Pharmaceuticals during the second quarter valued at approximately $7,162,000. Finally, Legal & General Group Plc bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $1,014,000. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on AMLX. HC Wainwright lifted their target price on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Wall Street Zen downgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Wolfe Research upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 17th. Finally, Guggenheim upped their target price on Amylyx Pharmaceuticals from $40.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $36.25.

Amylyx Pharmaceuticals Stock Down 1.0%

Amylyx Pharmaceuticals stock opened at $37.08 on Thursday. The stock has a 50-day moving average price of $21.72 and a 200 day moving average price of $17.20. The company has a market capitalization of $4.13 billion, a price-to-earnings ratio of -25.93 and a beta of -0.21. Amylyx Pharmaceuticals, Inc. has a 52 week low of $8.94 and a 52 week high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Research analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total value of $274,800.00. Following the sale, the insider owned 194,090 shares in the company, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 10.90% of the company’s stock.

About Amylyx Pharmaceuticals